<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541226</url>
  </required_header>
  <id_info>
    <org_study_id>2012_56</org_study_id>
    <secondary_id>2013-A00475-40</secondary_id>
    <nct_id>NCT03541226</nct_id>
  </id_info>
  <brief_title>Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)</brief_title>
  <acronym>cinocis</acronym>
  <official_title>Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop tools to detect, measure, monitor and predict axonal
      damage in the course of CIS and during Multiple sclerosis (MS), in order to be able to
      consider as early as possible an adaptation of the background treatment in patients with MS.
      patients with radiological criteria of poor long-term clinical course.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>severity of the disease defined by Expanded Disability Status Scale (EDSS) ≥ 2.0</measure>
    <time_frame>At 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a second push</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of progression of the EDSS (Expanded Disability Status Scale) score</measure>
    <time_frame>At 5 years</time_frame>
    <description>The scale evaluated the pyramidal, cerebellar, sensory, visual and mental functions . These make it possible to obtain a quotation between 0 and 10. The walk is called &quot;normal&quot; from 0 to 3.5. The walk is hampered from 4 and impossible from 7.5. The coast of 10 corresponds to the death of the patient.
This measure differentiates two groups: severe EDSS and non-severe EDSS group,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a handicap objectified by the Multiple Sclerosis Functional Composite(MSFC)</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variation of parameters measuring axonal pain / degeneration in MRI</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variation of parameters measuring axonal pain / degeneration in OCT</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Clinically Isolated Syndrome</condition>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patient with clinically isolated syndrome (CIS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient who has had a CIS of less than 4 months (+/- 15 days), with at least 1
             inflammatory lesion on his initial brain MRI or with normal brain MRI associated with
             the presence of oligoclonal bands in the CSF,

        Exclusion Criteria:

          -  Atypical CIS for a first relapse of multiple sclerosis (extensive myelitis, bilateral
             retrobulbar optic neuritis immediately)

          -  CIS dating more than 4 months (+/- 15 days)

          -  Corticotherapy in the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Outteryck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Outteryck, MD,PhD</last_name>
    <email>olivier.outteryck@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Vermersch, MD,PhD</last_name>
    <email>patrick.vermersch@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Vermersch, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Outteryck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

